DPS-2: A Novel Dual MEK/ERK and PI3K/AKT Pathway Inhibitor with Powerful Ex Vivo and In Vivo Anticancer Properties

DPS-2: A Novel Dual MEK/ERK and PI3K/AKT Pathway Inhibitor with Powerful Ex Vivo and In Vivo Anticancer Properties

Development of novel bioactive compounds against KRAS and/or BRAF mutant colorectal cancer (CRC) is currently an urgent need in oncology. In addition, single or multitarget kinase inhibitors against MEK/ERK and PI3K/AKT pathways are of potential therapeutic advantage. A new compound based on the ben...

Full description

Bibliographic Details
Main Authors: Maria Goulielmaki, Nikos Assimomytis, Jan Rozanc, Eleni Taki, Ioannis Christodoulou, Leonidas G. Alexopoulos, Vassilis Zoumpourlis, Alexandros Pintzas, Demetris Papahatjis
Format: Article
Language:English
Published: Elsevier 2019-07-01
Series:Translational Oncology
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523319300130

Internet

http://www.sciencedirect.com/science/article/pii/S1936523319300130

Similar Items